... WhatsApp

Apalutamide May Help Men with Advanced Prostate Cancer Live Longer Than Abiraterone

You are here >> Home > Latest Updates > Prostate Cancer > Apalutamide May…

Apalutamide May Help Men with Advanced Prostate Cancer Live Longer Than Abiraterone

Men with metastatic castration-sensitive prostate cancer (mCSPC) have cancer that has spread beyond the prostate but still responds to hormone-blocking treatment. Several medicines can be added to standard hormone therapy to help patients live longer, including apalutamide and abiraterone. Until now, there had not been a direct comparison between these two drugs in real-world patients.

A new study in the United States looked at nearly 4,000 men with mCSPC who were starting treatment for the first time with either apalutamide or abiraterone. Both groups of patients were similar in age (average 72 years), race, and cancer stage.

The results showed that men who received apalutamide had a better chance of survival than those who received abiraterone. At 24 months after starting treatment, men in the apalutamide group had a 26% lower risk of death compared with those in the abiraterone group. This benefit was also seen when researchers followed patients for longer.

Both apalutamide and abiraterone remain important treatment options, but this study suggests that apalutamide may give men with advanced prostate cancer an advantage in survival.

Patients should speak with their doctors about which medicine is best for them, since treatment choice can also depend on other health conditions, side effects, and cost.

Rate this post

Exclusive Health Tips and Updates

dr swati shah - uro & gynec cancer surgeon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.